Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches off another. These areas are particularly difficult to treat and occur frequently, in two out of ten cases – or approximately half a million procedures annually.

Bifurcation lesions have presented a challenge for cardiologists since the earliest days of angioplasty. Current approaches to treating these lesions have significant limitations – they are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation.

Tryton Medical, Inc. was founded in 2003 by Aaron V. Kaplan, M.D. and Spray Venture Partners with a single mission: to become the leading developer of novel stent systems for the treatment of bifurcation lesions.

Tryton’s innovative solution to the persistent problem presented by bifurcation lesions is the Tryton Side Branch Stent System™, which offers a dedicated strategy for bifurcation stenting. This unique system has demonstrated excellent initial clinical results and is available in Europe.

The company believes that the ability to definitively treat bifurcation lesions may someday allow stenting to become the new standard of care for left main coronary artery disease, providing an alternative to coronary bypass surgery, an invasive procedure that involves longer recovery times and higher costs.

Tryton is uniquely positioned for success, with management that has more than 60 years of collective experience in the medical technology arena. This leadership team has taken a variety of products from inception to commercialization at leading companies including Abbott, Boston Scientific, Guidant, and Johnson & Johnson. The company’s board of directors and scientific advisors include veterans of the medical device industry and prominent thought leaders in cardiology today.

The company is privately held, with backing from Spray Ventures, PTV Sciences, and RiverVest Ventures.